Efficacy News and Research

RSS

Health Canada approves Sunovion’s LATUDA NDA to treat schizophrenia

Sunovion Pharmaceuticals Canada Inc. today announced that the New Drug Submission (NDS) for LATUDA (lurasidone HCl), for the treatment of adult patients with acute schizophrenia has been approved by Health Canada.

16 Jun 2012

Insulin more effective add-on than sitagliptin in glucose control

Insulin seems to be a more effective add-on regimen than sitagliptin in patients with diabetes inadequately controlled by metformin monotherapy, show study findings.

15 Jun 2012

Positive top-line results from Teva’s GALA Phase III trial on RRMS

Teva Pharmaceutical Industries Ltd. today announced positive top-line results from the GALA (Glatiramer Acetate Low-Frequency Administration) Phase III clinical trial assessing the efficacy, safety and tolerability of 40 mg/1 ml glatiramer acetate injection (GA) administered subcutaneously three times a week compared to placebo in relapsing-remitting multiple sclerosis (RRMS) patients.

15 Jun 2012

NIH awards $9 million grant to study aging and immunity to infections

The Trudeau Institute today announced that faculty member Laura Haynes, Ph.D., was awarded a grant from the National Institutes of Health (NIH) to study how aging impacts the immune system's response to influenza infection and vaccination.

15 Jun 2012

Third Rock Ventures announces formation of Global Blood Therapeutics

Third Rock Ventures, LLC today announced the formation of Global Blood Therapeutics, Inc. and its $40.7 million Series A financing of the company.

15 Jun 2012

Dyax to discontinue ecallantide Phase 2 trial for ACE inhibitor-induced angioedema

Dyax Corp. announced today the decision to discontinue the Company's Phase 2 trial investigating ecallantide in the acute treatment of angiotensin converting enzyme (ACE) inhibitor-induced angioedema based upon the results of an interim analysis.

15 Jun 2012

MRF announces achievement of myelin repair Phase 1 trial for MS

The Myelin Repair Foundation (MRF) today announced the achievement of a myelin repair Phase 1 clinical trial for multiple sclerosis earlier than the foundation's goal set for 2014. By establishing its Accelerated Research Collaboration (ARC) Model to advance myelin repair treatments forward into clinical trial Phase 1 within a decade, the Myelin Repair Foundation achieved this critical milestone ahead of its goal, validating the efficiency of the ARC model to speed drug development.

15 Jun 2012

Hay fever vaccine shows efficacy in phase IIa trial

A novel vaccine for grass pollen allergy has shown significant improvements for patients in a Phase IIa trial. The vaccine BM32 is based on an innovative recombinant peptide carrier technology that allows for fewer injections and shows fewer side effects compared with other immunotherapy treatments for allergy sufferers. BM32 has been developed by Biomay AG, an Austrian biopharmaceutical company specialized in the discovery and development of innovative allergy therapeutics. The company has already initiated a Phase IIb trial for BM32 with 180 allergic patients.

14 Jun 2012

European launch of technology for quantitative assessment of Parkinson’s disease symptoms from Great Lakes NeuroTechnologies

Great Lakes NeuroTechnologies announced today that they are launching the latest version of their medical device technology for assessing Parkinson’s disease next week at the Movement Disorders Society Congress in Dublin, Ireland.

14 Jun 2012

AB Science announces results from masitinib phase 2 study on MS

AB Science SA, a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors, announces the publication of results from the human phase 2 study of masitinib carried-out in the treatment of progressive multiple sclerosis.

14 Jun 2012

Advaxis announces publication of preclinical research with ADXS-PSA

Advaxis, Inc., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced the publication of preclinical research with ADXS-PSA (ADXS31-142), Advaxis' Lm-LLO immunotherapy targeting the PSA antigen associated with prostate cancer.

14 Jun 2012

NEJM hails vismodegib as ‘the greatest advance in therapy yet seen’ for advanced BCC

Vismodegib, a new skin cancer drug for patients with advanced basal cell carcinoma tested by TGen, Virginia G. Piper Cancer Center at Scottsdale Healthcare and Mayo Clinic, is hailed as "the greatest advance in therapy yet seen" for advanced basal cell carcinoma in an editorial in the New England Journal of Medicine.

14 Jun 2012

Interactive website improves parental compliance with asthma controller medication use

Asthma is the most common chronic illness in adolescents and children, affecting an estimated seven million children up to the age of 17 in the United States. The burden of asthma on children is substantial: kids with asthma have a three-fold greater risk of school absence than children without asthma, and asthma is the third leading cause of hospitalization among children under the age of 15.

14 Jun 2012

Ophthotech’s Fovista anti-PDGF combination therapy superior to Lucentis for wet AMD

Ophthotech Corporation today announced results from the first clinical trial to show statistically significant superior efficacy over Lucentis (ranibizumab) monotherapy for the treatment of neovascular age-related macular degeneration (wet AMD).

14 Jun 2012

EnVivo to present results from EVP-6124 Phase 2b trial on AD at AAIC 2012

EnVivo Pharmaceuticals, a company dedicated to developing a broad range of novel central nervous system (CNS) therapies, today announced that the company will present a comprehensive analysis of its recently completed Phase 2b clinical trial of EVP-6124 in Alzheimer's disease at the Alzheimer's Association International Conference 2012 (AAIC), being held July 14-19, 2012 in Vancouver, British Columbia.

14 Jun 2012

Enrollment complete in Endosense’s TactiCath catheter clinical study for paroxysmal AF

Endosense,a pioneer and leader in force-sensing technology focused on improving the efficacy and safety of catheter ablation for the treatment of cardiac arrhythmias, has announced enrollment completion in the TOCCASTAR clinical study.

14 Jun 2012

Investigational Insomnia Medicine from Merck improved patients’ ability to fall and stay asleep according to new phase III Data

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced new data from two pivotal Phase III efficacy trials for suvorexant, the investigational medicine Merck is developing for the treatment of insomnia. In the studies, suvorexant significantly reduced the time it took patients to fall asleep and increased the time that patients stayed asleep as early as the first night and at the three-month time point compared to placebo. The investigational medicine met statistical significance for all primary endpoints except for one measurement at Month 3 in one of the trials. These late-breaking data were presented here today at SLEEP 2012, the 26th Annual Meeting of the Associated Professional Sleep Societies.

13 Jun 2012

ChromaDex’s pTeroPure safe for human consumption

ChromaDex Corporation, an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & beverage, animal health, cosmetic and pharmaceutical industries announced today its patented pTeroPure (pterostilbene) was shown to be safe for human consumption according to data from the first clinical trial of the substance.

13 Jun 2012

Acorda commences AMPYRA clinical study for post-stoke deficits

Acorda Therapeutics, Inc. today announced that the first patient has been enrolled in a proof-of-concept study exploring the use of AMPYRA(dalfampridine) Extended Release Tablets, 10 mg in treating patients who have post-stroke deficits.

13 Jun 2012

New approach can design antibiotics that kill even 'superbugs'

The world needs new antibiotics to overcome the ever increasing resistance of disease-causing bacteria - but it doesn't need the side effect that comes with some of the most powerful ones now available: hearing loss. Today, researchers report they have developed a new approach to designing antibiotics that kill even "superbugs" but spare the delicate sensory cells of the inner ear.

12 Jun 2012